Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/09/20
Biohaven To Report Third Quarter 2020 Financial Results And Recent Business Developments On November 9, 2020PRNewsWire • 10/30/20
U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of MigrainePRNewsWire • 10/14/20
Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human DosingPRNewsWire • 09/10/20
BiohavenPharmaHldg Reaches 80-Plus Relative Strength Rating BenchmarkInvestors Business Daily • 09/08/20
Biohaven Pharmaceutical Holding Company Ltd (BHVN) CEO Vladimir Coric on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/10/20
Biohaven Reports Second Quarter 2020 Financial Results And Recent Business DevelopmentsPRNewsWire • 08/10/20
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 MillionPRNewsWire • 08/07/20
Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General HospitalPRNewsWire • 08/03/20
Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System AtrophyPRNewsWire • 07/21/20
Leading Biotech Stock Crumbles After OCD Drug Flops In Midstage TestInvestors Business Daily • 06/24/20
Biohaven Presents NURTEC™ (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific MeetingPRNewsWire • 06/16/20
Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC™ ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual PlatformPRNewsWire • 05/18/20